Janssen R&D Ireland clinical trials

Acquired by Johnson & Johnson, Apr 2002 · source ↗

The registry lists 32 studies whose lead sponsor is Janssen R&D Ireland. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Dec 9, 2021.

Studies

Recruiting first, then most recently updated. Showing 32 of 32. All Johnson & Johnson studies →

• Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Regimen Versus Boosted Protease Inhibitor (bPI) Along With Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) Regimen in Virologically-Suppressed, HIV-1 Infected ParticipantsCompletedNCT02269917Phase 3

  Sponsor listed in the registry: Janssen R&D Ireland · First submitted after Janssen R&D Ireland became part of Johnson & Johnson

• A Trial With TMC278-TIDP6-C222 for Continued TMC278 Access in Patients Infected With Human Immunodeficiency Virus-1CompletedNCT01266902Phase 3

  Sponsor listed in the registry: Janssen R&D Ireland · First submitted after Janssen R&D Ireland became part of Johnson & Johnson

• A Study of the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of JNJ-47910382 at Different Doses and Dose Regimens in Asian Genotype-1, Chronic, HCV-Infected PatientsTerminatedNCT01586325Phase 1

  Sponsor listed in the registry: Janssen R&D Ireland · First submitted after Janssen R&D Ireland became part of Johnson & Johnson

• A Study of Pharmacokinetics, Efficacy, Safety, Tolerability, of the Combination of Simeprevir (TMC435), Daclatasvir (BMS-790052), and Ribavirin (RBV) in Patients With Recurrent Chronic Hepatitis C Genotype 1b Infection After Orthotopic Liver TransplantationCompletedNCT01938625Phase 2

  Sponsor listed in the registry: Janssen R&D Ireland · First submitted after Janssen R&D Ireland became part of Johnson & Johnson

• A Study to Evaluate the Efficacy, Safety and Tolerability of TMC435 in Combination With PegIFN Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment-Naïve or Treatment-Experienced, Chronic Hepatitis C Virus Genotype-4 Infected PatientsCompletedNCT01567735Phase 3

  Sponsor listed in the registry: Janssen R&D Ireland · First submitted after Janssen R&D Ireland became part of Johnson & Johnson

• 3-year Follow-up Study in Patients Previously Treated With TMC435-Containing Regimen for the Treatment of Hepatitis C Virus InfectionCompletedNCT01349465Phase 3

  Sponsor listed in the registry: Janssen R&D Ireland · First submitted after Janssen R&D Ireland became part of Johnson & Johnson

• Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Subjects With Chronic Genotype 4 Hepatitis C Virus InfectionCompletedNCT02250807Phase 3

  Sponsor listed in the registry: Janssen R&D Ireland · First submitted after Janssen R&D Ireland became part of Johnson & Johnson

• TMC435HPC3001 - An Efficacy, Safety and Tolerability Study for TMC435 vs Telaprevir in Combination With PegINFα-2a and Ribavirin in Chronic Hepatitis C Patients Who Were Null or Partial Responders to Prior PegINFα-2a and Ribavirin TherapyCompletedNCT01485991Phase 3

  Sponsor listed in the registry: Janssen R&D Ireland · First submitted after Janssen R&D Ireland became part of Johnson & Johnson

• A Study of TMC435 in Combination With Peginterferon Alfa-2A and Ribavirin for Hepatitis C Virus Genotype-1 Infected Patients Who Participated in a Control Group of a TMC435 StudyCompletedNCT01323244Phase 3

  Sponsor listed in the registry: Janssen R&D Ireland · First submitted after Janssen R&D Ireland became part of Johnson & Johnson

• A Study to Evaluate the Safety, Tolerability, and Effectiveness of a 12-Week Combination Therapy of TMC647055 and TMC435 With and Without GSK23336805 With a Pharmacokinetic Enhancer With and Without Ribavirin in Patients Infected With Chronic Genotype 1 Hepatitis C VirusCompletedNCT01724086Phase 2

  Sponsor listed in the registry: Janssen R&D Ireland · First submitted after Janssen R&D Ireland became part of Johnson & Johnson

• A Study in Japanese Children Hospitalized With Respiratory Syncytial Virus Related Lower Respiratory Tract InfectionsCompletedNCT02132923

  Sponsor listed in the registry: Janssen R&D Ireland · First submitted after Janssen R&D Ireland became part of Johnson & Johnson

• An Efficacy, Pharmacokinetics, Safety and Tolerability Study of TMC435 as Part of a Treatment Regimen for Hepatitis C-Infected PatientsCompletedNCT01725529Phase 3

  Sponsor listed in the registry: Janssen R&D Ireland · First submitted after Janssen R&D Ireland became part of Johnson & Johnson

• An Efficacy, Safety, Tolerability and Pharmacokinetics Study of 12 Weeks Treatment With Simeprevir and Daclatasvir in Participants With Chronic Hepatitis C Virus Genotype 1b or 4 Infection and Either Severe Renal Impairment or End-stage Renal Disease on Hemodialysis.WithdrawnNCT02397395Phase 2

  Sponsor listed in the registry: Janssen R&D Ireland · First submitted after Janssen R&D Ireland became part of Johnson & Johnson

• A Study of TMC435 in Combination With PSI-7977 (GS7977) in Chronic Hepatitis C Genotype 1-Infected Prior Null Responders To Peginterferon/Ribavirin Therapy or HCV Treatment-Naive PatientsCompletedNCT01466790Phase 2

  Sponsor listed in the registry: Janssen R&D Ireland · First submitted after Janssen R&D Ireland became part of Johnson & Johnson

• A Study to Assess the Safety, Tolerability and Efficacy of TMC435 Along With Pegylated Interferon Alpha-2a (Pegasys) and Ribavirin (Copegus) Triple Therapy in Chronic Hepatitis C Genotype-1 Infected Patients Co-infected With Human Immunodeficiency Virus-Type 1CompletedNCT01479868Phase 3

  Sponsor listed in the registry: Janssen R&D Ireland · First submitted after Janssen R&D Ireland became part of Johnson & Johnson

• A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Etravirine Administered in Combination With Other Antiretroviral Agents in Antiretroviral Treatment-Experienced HIV-1 Infected PatientsCompletedNCT01422330Phase 4

  Sponsor listed in the registry: Janssen R&D Ireland · First submitted after Janssen R&D Ireland became part of Johnson & Johnson

• A Study to Investigate the Safety, Tolerability and Pharmacokinetics of GSK2336805 Alone and With the Co-administration of TMC435 in Healthy Japanese Participants.CompletedNCT02018536Phase 1

  Sponsor listed in the registry: Janssen R&D Ireland · First submitted after Janssen R&D Ireland became part of Johnson & Johnson

• An Efficacy, Safety, and Tolerability Study of TMC435 in Treatment-naive, Genotype 1 Hepatitis C-infected ParticipantsCompletedNCT01290679Phase 3

  Sponsor listed in the registry: Janssen R&D Ireland · First submitted after Janssen R&D Ireland became part of Johnson & Johnson

• An Efficacy, Safety, and Tolerability Study of TMC435 in Treatment-naive, Genotype 1 Hepatitis C-infected PatientsCompletedNCT01289782Phase 3

  Sponsor listed in the registry: Janssen R&D Ireland · First submitted after Janssen R&D Ireland became part of Johnson & Johnson

• A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of TMC647055 in Combination With Ritonavir (Part 1) and the Co-administration of TMC435, TMC647055 and Ritonavir (Part 2) in Healthy Japanese ParticipantsCompletedNCT02064842Phase 1

  Sponsor listed in the registry: Janssen R&D Ireland · First submitted after Janssen R&D Ireland became part of Johnson & Johnson

• Study in HCV-Infected Patients to Determine the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of JNJ-47910382TerminatedNCT01651767Phase 1

  Sponsor listed in the registry: Janssen R&D Ireland · First submitted after Janssen R&D Ireland became part of Johnson & Johnson

• An Efficacy, Safety and Tolerability Study of TMC435 in Genotype 1 Hepatitis C-infected Patients Who Relapsed After Previous TherapyCompletedNCT01281839Phase 3

  Sponsor listed in the registry: Janssen R&D Ireland · First submitted after Janssen R&D Ireland became part of Johnson & Johnson

• A Study to Explore the Pharmacokinetics of Rilpivirine With Rifabutin in Healthy ParticipantsCompletedNCT01615614Phase 1

  Sponsor listed in the registry: Janssen R&D Ireland · First submitted after Janssen R&D Ireland became part of Johnson & Johnson

• A Study to Assess the Absolute Bioavailability and Pharmacokinetics of Simeprevir (TMC435) Administered as Single Oral Doses of TMC435 and an Intravenous Microdose of [3H]-TMC435 in Healthy Male PatientsCompletedNCT01707342Phase 1

  Sponsor listed in the registry: Janssen R&D Ireland · First submitted after Janssen R&D Ireland became part of Johnson & Johnson

• A Study to Explore Pharmacokinetic Interaction Between Rilpivirine and Metformin in Healthy ParticipantsCompletedNCT01719614Phase 1

  Sponsor listed in the registry: Janssen R&D Ireland · First submitted after Janssen R&D Ireland became part of Johnson & Johnson

• Study to Examine Multiple Doses of TMC647055 in Combination With TelaprevirCompletedNCT01582035Phase 1

  Sponsor listed in the registry: Janssen R&D Ireland · First submitted after Janssen R&D Ireland became part of Johnson & Johnson

• TMC125-TiDP2-C238: An Exploratory Pharmacokinetics, Safety and Anti-HIV Activity Study of Etravirine (ETR) When Given With Boosted Atazanavir (ATV/Rtv) at Two Different Doses and 1 Nucleoside Reverse Transcriptase Inhibitor (NRTI) in Treatment Experienced HIV PatientsCompletedNCT00896051Phase 2

  Sponsor listed in the registry: Janssen R&D Ireland · First submitted after Janssen R&D Ireland became part of Johnson & Johnson

• A Study to Compare the Bioavailability of JNJ-47910382 Formulated as a Tablet and as Suspension in Healthy ParticipantsCompletedNCT01662661Phase 1

  Sponsor listed in the registry: Janssen R&D Ireland · First submitted after Janssen R&D Ireland became part of Johnson & Johnson

• A Study to Assess Bioavailability & Food Effect of Different Liquid and Capsule Formulations of TMC435.CompletedNCT01571570Phase 1

  Sponsor listed in the registry: Janssen R&D Ireland · First submitted after Janssen R&D Ireland became part of Johnson & Johnson

• A Study to Assess the Bioequivalence of Darunavir When Co-Administrated With Cobicistat Under Fed and Fasted ConditionsCompletedNCT01619527Phase 1

  Sponsor listed in the registry: Janssen R&D Ireland · First submitted after Janssen R&D Ireland became part of Johnson & Johnson

• A Study to Investigate the Effect of Steady-State TMC278 on the Pharmacokinetics of a Single Dose of DigoxinCompletedNCT01519128Phase 1

  Sponsor listed in the registry: Janssen R&D Ireland · First submitted after Janssen R&D Ireland became part of Johnson & Johnson

• A Study in Healthy Participants Investigating the Safety, Tolerability and Plasma Pharmacokinetics (PK) of Single Oral Doses of JNJ-47910382CompletedNCT01482611Phase 1

  Sponsor listed in the registry: Janssen R&D Ireland · First submitted after Janssen R&D Ireland became part of Johnson & Johnson